Literature DB >> 17084877

Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion.

Elaine R Thomas1, Rebecca L Dunfee, Jennifer Stanton, Derek Bogdan, Joann Taylor, Kevin Kunstman, Jeanne E Bell, Steven M Wolinsky, Dana Gabuzda.   

Abstract

HIV infects macrophages and microglia in the central nervous system (CNS), which express lower levels of CD4 than CD4+ T cells in peripheral blood. To investigate mechanisms of HIV neurotropism, full-length env genes were cloned from autopsy brain and lymphoid tissues from 4 AIDS patients with HIV-associated dementia (HAD). Characterization of 55 functional Env clones demonstrated that Envs with reduced dependence on CD4 for fusion and viral entry are more frequent in brain compared to lymphoid tissue. Envs that mediated efficient entry into macrophages were frequent in brain but were also present in lymphoid tissue. For most Envs, entry into macrophages correlated with overall fusion activity at all levels of CD4 and CCR5. gp160 nucleotide sequences were compartmentalized in brain versus lymphoid tissue within each patient. Proline at position 308 in the V3 loop of gp120 was associated with brain compartmentalization in 3 patients, but mutagenesis studies suggested that P308 alone does not contribute to reduced CD4 dependence or macrophage-tropism. These results suggest that HIV adaptation to replicate in the CNS selects for Envs with reduced CD4 dependence and increased fusion activity. Macrophage-tropic Envs are frequent in brain but are also present in lymphoid tissues of AIDS patients with HAD, and entry into macrophages in the CNS and other tissues is dependent on the ability to use low receptor levels and overall efficiency of fusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084877      PMCID: PMC1890014          DOI: 10.1016/j.virol.2006.09.036

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  113 in total

1.  Biology of adult human microglia in culture: comparisons with peripheral blood monocytes and astrocytes.

Authors:  K Williams; A Bar-Or; E Ulvestad; A Olivier; J P Antel; V W Yong
Journal:  J Neuropathol Exp Neurol       Date:  1992-09       Impact factor: 3.685

2.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

3.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

4.  Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences.

Authors:  B T Korber; K J Kunstman; B K Patterson; M Furtado; M M McEvilly; R Levy; S M Wolinsky
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

5.  Signature pattern analysis: a method for assessing viral sequence relatedness.

Authors:  B Korber; G Myers
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

6.  HIV receptors within the brain: a study of CD4 and MHC-II on human neurons, astrocytes and microglial cells.

Authors:  S Peudenier; C Héry; K H Ng; M Tardieu
Journal:  Res Virol       Date:  1991 Mar-Jun

7.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages.

Authors:  S R Lewin; S Sonza; L B Irving; C F McDonald; J Mills; S M Crowe
Journal:  AIDS Res Hum Retroviruses       Date:  1996-07-01       Impact factor: 2.205

10.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

Authors:  M Purtscher; A Trkola; G Gruber; A Buchacher; R Predl; F Steindl; C Tauer; R Berger; N Barrett; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-12       Impact factor: 2.205

View more
  82 in total

1.  A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.

Authors:  Thomas Musich; Paul J Peters; Maria José Duenas-Decamp; Maria Paz Gonzalez-Perez; James Robinson; Susan Zolla-Pazner; Jonathan K Ball; Katherine Luzuriaga; Paul R Clapham
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

2.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 3.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction.

Authors:  K Grovit-Ferbas; M E Harris-White
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

4.  Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study.

Authors:  Robert E Donahue; Sharat Srinivasula; Naoya Uchida; Insook Kim; Alexis St Claire; Gorka Duralde; Paula DeGrange; Marisa St Claire; Richard C Reba; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Chang H Paik; H Clifford Lane; John F Tisdale; Michele Di Mascio
Journal:  Blood       Date:  2015-10-22       Impact factor: 22.113

5.  Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Authors:  Jonathan Toma; Steven P Weinheimer; Eric Stawiski; Jeannette M Whitcomb; Stanley T Lewis; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

6.  Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.

Authors:  Anjali Joshi; Raphael T C Lee; Jonathan Mohl; Melina Sedano; Wei Xin Khong; Oon Tek Ng; Sebastian Maurer-Stroh; Himanshu Garg
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

7.  Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities.

Authors:  Sarah B Joseph; Kathryn T Arrildt; Adrienne E Swanstrom; Gretja Schnell; Benhur Lee; James A Hoxie; Ronald Swanstrom
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

8.  HIV gp120 sequence variability associated with HAND in Hispanic Women.

Authors:  Krystal Colón; Fabián Vázquez-Santiago; Vanessa Rivera-Amill; Gisela Delgado; Steven E Massey; Valerie Wojna; Richard J Noel; Loyda M Meléndez
Journal:  J Virol Antivir Res       Date:  2015-10-06

9.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

10.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.